Mannosylated lipid nano-emulsions loaded with lycorine-oleic acid ionic complex for tumor cell-specific delivery

Theranostics

Volumn 2, Issue 11, 2012, Pages 1104-1114

  Guo, Yangming ^a   Liu, Xing ^a   Sun, Xun ^a   Zhang, Qiang ^b   Gong, Tao ^a,c   Zhang, Zhirong ^a  

^a SICHUAN UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH   (China)

Author keywords

Lipid nano emulsion; Lycorine; Mannosylation; Tumor targeted delivery

Indexed keywords

LYCORINE; OLEIC ACID; SOLVENT;

ARTICLE; ASSAY; CANCER INHIBITION; CONTROLLED STUDY; DISPERSION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SYNTHESIS; IN VITRO STUDY; LIPOPHILICITY; NANOEMULSION; PARTICLE SIZE; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL; ZETA POTENTIAL;

LIPID NANO-EMULSION; LYCORINE; MANNOSYLATION; TUMOR TARGETED DELIVERY.;

AMARYLLIDACEAE ALKALOIDS; ANIMALS; CELL PROLIFERATION; CHEMISTRY, PHARMACEUTICAL; CHO CELLS; CRICETINAE; CRICETULUS; DRUG DELIVERY SYSTEMS; EMULSIONS; INHIBITORY CONCENTRATION 50; INTRACELLULAR SPACE; IONS; MANNOSE; MICROSCOPY, CONFOCAL; NANOPARTICLES; NEOPLASMS; OLEIC ACID; PARTICLE SIZE; PHENANTHRIDINES; SOLUBILITY; STATIC ELECTRICITY;

EID: 84870567200     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.4525     Document Type: Article

References (32)

1. Qin K, Li X, Xu S, et al. A Survey of the Studies on Pharmacological Effects of Lycorine and Its Derivatives. Journal of Beijing Union University( Natural Science). 2009; 23(1): 6-10.
2. Li SY, Chen C, Zhang HY, et al. Identification of natural compounds with antiviral activities against SARS-associated coronavirus. Antiviral Research. 2005; 67(1): 18-23.
3. Zou G, Puig-Basagoiti F, Zhang B, et al. A single-amino acid substitution in West Nile virus 2K peptide between NS4A and NS4B confers resistance to lycorine, a flavivirus inhibitor. Virology. 2009; 384(1): 242-52.
4. Barbosa-Filho JM, Piuvezam MR, Moura MD, et al. Anti-inflammatory activity of alkaloids: a twenty-century review. Revista Brasileira de Farmacognosia. 2006; 16(1): 109-139.
5. Sener B, Orhan I, and Satayavivad J. Antimalarial activity screening of some alkaloids and the plant extracts from Amaryllidaceae. Phytotherapy Research. 2003; 17(10): 1220-3.
6. Ingrassia L, Lefranc F, et al. Amaryllidaceae isocarbostyril alkaloids and their derivatives as promising antitumor agents. Translational Oncology. 2008; 1(1): 1-13.
7. Lamoral-theys D, Andolfi A, Goietsenoven GV, et al. Lycorine, the main phenanthridine amaryllidaceae alkaloid, exhibits significant antitumor activity in cancer cells that display resistance to proapoptotic stimuli: an investigation of structure-activity relationship and mechanistic insight. Journal of Medicinal Chemistry. 2009; 52: 6244-56.
8. Solans C, Izquierdo P, Nolla J, et al. Nano-emulsions. Current Opinion in Colloid & Interface Science. 2005; 10(3-4): 102 - 110.
9. Pey CM, Maestro A, Solé I, et al. Optimization of nano-emulsions prepared by low-energy emulsification methods at constant temperature using a factorial design study. Colloids and Surfaces A: Physicochemical and Engineering Aspects. 2006; 288(1-3): 144-150.
10. Simonnet J. and Alloret FL. Nanoemulsions: a new vehicle for skincare products. Advances in Colloid and Interface Science. 2004; 20(108-109): 145-9.
11. Baluom M, Friedman DI and Rubinstein A. Absorption enhancement of calcitonin in the rat intestine by carbopol-containing submicron emulsions. International Journal of Pharmaceutics. 1997;154(2): 235-243.
12. Santos-Magalhães NS, Pontes A, Pereira VM, et al. Colloidal carriers for benzathine penicillin G: nanoemulsions and nanocapsules. International Journal of Pharmaceutics. 2000; 208(1-2): 71-80.
13. Managit C, Kawakami S, Yamashita F, et al. Uptake characteristics of galactosylated emulsion by HepG2 hepatoma cells. International Journal of Pharmaceutics. 2005; 301(1-2): 255-61.
14. Yeeprae W, Kawakami S, Higuchi Y, et al. Biodistribution characteristics of mannosylated and fucosylated O/W emulsions in mice. Journal of Drug Targeting. 2005; 13(8-9): 479-87.
15. Agarwal A, Saraf S, Asthana A, et al. Ligand based dendritic systems for tumor targeting. International Journal of Pharmaceutics. 2008; 350(1-2): 3-13.
16. Jain A, Agarwal A, Majumder S, et al. Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug. Journal of Controlled Release. 2010;148(3): 359-67.
17. Schubert MA and Müller-Goymann CC. Solvent injection as a new approach for manufacturing lipid nanoparticles - evaluation of the method and process parameters. European Journal of Pharmaceutics and Biopharmaceutics. 2003; 55(1): 125-31.
18. Ames GR, et al. Long-Chain Derivatives of Sugars. I. Some Reaction of N-Octadecy-D-glucosylamine. Journal of Organic Chemistry. 1962; 27(2): 390-395.
19. Yue PF, Lu XY, Zhang ZZ, et al. The study on the entrapment efficiency and In Vitro release of puerarin submicron emulsion. AAPS Pharm Sci Tech. 2009; 10(2): 376-83.
20. Higashiyama M, Inada K, Ohtori A, et al. Improvement of the ocular bioavailability of timolol by sorbic acid. International Journal of Pharmaceutics. 2004; 272(1-2): 91-8.
21. Sznitowska M, Zurowska-pryczkowska K, et al. Increased partitioning of pilocarpine to the oily phase of submicron emulsion does not result in improved ocular bioavailability. International Journal of Pharmaceutics. 2000; 202(1-2): 161 - 4.
22. Higashiyama M, Inada K, Ohtori A, et al. NMR analysis of ion pair formation between timolol and sorbic acid in ophthalmic preparations. Journal of Pharmaceutical and Biomedical Analysis. 2007; 43(4): 1335-42.
23. Freitas C and Müller RH. Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLN ™) dispersions. International Journal of Pharmaceutics. 1998; 168(2): 221-229.
24. Zhang, X, Sun X, Li J, et al. Lipid nanoemulsions loaded with doxorubicin-oleic acid ionic complex: characterization, in vitro and in vivo studies. Die Pharmazie. 2011; 66(7): 496-505.
25. Tamilvanan S, Schmidt S, Müller RH, et al. In vitro adsorption of plasma proteins onto the surface (charges) modified-submicron emulsions for intravenous administration. European Journal of Pharmaceutics and Biopharmaceutics. 2005; 59(1): 1-7.
26. Wang X, Wang Y, Chen ZG et al. Advances of cancer therapy by nanotechnology. Cancer Research and Treatment. 2009; 41(1):1-11.
27. Minko T. Drug targeting to the colon with lectins and neoglycoconjugates. Advanced Drug Delivery Review. 2004; 56(4): 491-509.
28. Seymour LW, Ferry DR, Anderson D, et al. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. Journal of Clinical Oncology. 2002; 20(6): 1668-76.
29. Le Cabec V, Emorine LJ, Toesca I, et al. The human macrophage mannose receptor is not a professional phagocytic receptor. Journal of Leukocyte Biology. 2005; 77(6):934-43
30. Wu F, Wuensch SA, Azadniv M, et al. Galactosylated LDL nanoparticles: a novel targeting delivery system to deliver antigen to macrophages and enhance antigen specific T cell responses. Molecular Pharmaceutics. 2009, 6(5):1506-17.
31. Calder PC. Hot topics in parenteral nutrition. Rationale for using new lipid emulsions in parenteral nutrition and a review of the trials performed in adults. The Proceedings of the Nutrition Society. 2009; 68(3): 252-60.
32. Tamilvanan S. Oil-in-water lipid emulsions: implications for parenteral and ocular delivering systems. Progress in Lipid Research. 2004; 43(6): 489-533.